Surrey Heartlands

Joint Formulary & PAD

Rituximab - Immune thrombocytopenia

You are here : Home > Formulary Search > Rituximab - Immune thrombocytopenia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
ICB
Un
Restrictions / Comments :

Rituximab is off-label for this indication. Prescribing to be retained by hospital specialists only. 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Rituximab
Indication :
Immune thrombocytopenia
Group Name :
Keywords :
ITP
Brand Names Include :
MabThera, Rixathon, Truxima
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Immune thrombocytopenia
Supporting Documents :
0

Other Indications

Below are listed other indications that Rituximab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Immune thrombocytopenia.

Committee Recommendations (2)

03 Jun 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Rituximab is off-label for this indication. Prescribing to be retained by hospital specialists only. 

Added 10/01/2025 for clarity.

‘Rituximab will be considered RED on the traffic light system. Prescribing will be by hospital specialists only. Please note: a pathway for the use of thrombopoietin receptor agonists (TPO-RAs) and fostamatinib in the treatment of immune thrombocytopenia in adults is available in the guidelines section of the PAD’.

08 Jul 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.